Insulin Aspart: Uses, Mechanism, and Side Effects

Key takeaways

• Insulin aspart is a rapid-acting human insulin analog sold under the brand name NovoLog.
• It is approved to improve glycemic control in adults and pediatric patients with diabetes mellitus.
• The label does not carry a boxed warning.
• Over 600 registered trials have studied insulin aspart and related formulations, including biosimilar comparisons.
• FDA Adverse Event Reporting System data show blood glucose changes and gastrointestinal complaints as the most frequently reported reactions.

What Insulin Aspart Is

Insulin aspart belongs to the insulin analog drug class. It works by regulating glucose metabolism the way natural insulin does, but it is engineered to act rapidly. It lowers blood glucose by prompting muscle and fat tissue to take up glucose from the bloodstream and by reducing glucose production in the liver. The compound also slows the breakdown of fat and protein while supporting protein synthesis, mirroring the broader physiological role of insulin in the body.

What Insulin Aspart Is Approved For

Insulin aspart, marketed as NovoLog, is approved to improve glycemic control in adults and children with diabetes mellitus. The label does not identify a specific diabetes subtype restriction, positioning it as a broad glycemic control therapy. No boxed warning appears on the label.

What the Evidence Shows

More than 600 trials have registered insulin aspart or closely related formulations. A completed phase 1 study, the AT278 and NovoRapid glucose clamp trial, examined its pharmacologic profile in controlled conditions. A completed phase 2/3 study compared the pharmacokinetics and pharmacodynamics of a proposed biosimilar insulin aspart against NovoLog in healthy volunteers, reflecting ongoing interest in interchangeable rapid-acting insulin products. A separate post-marketing surveillance study evaluated a biphasic insulin aspart formulation in real-world use.

Reported Side Effects

Reports submitted to the FDA Adverse Event Reporting System most commonly describe changes in blood glucose, with blood glucose increases reported over 10,000 times and blood glucose decreases reported more than 3,000 times. These counts reflect how often a reaction was reported, not confirmed incidence or a proven causal link. Gastrointestinal complaints also appear frequently, including nausea, diarrhoea, and vomiting, alongside reports of fatigue, dyspnoea, and cases describing the drug as ineffective.